Literature DB >> 33072493

Listeria monocytogenes cancer vaccines: bridging innate and adaptive immunity.

Zachary T Morrow1, Zachary M Powers1, John-Demian Sauer2.   

Abstract

PURPOSE OF THE REVIEW: Immunotherapy has emerged as a promising cancer treatment, however success in only select clinical indications underscores the need for novel approaches. Recently Listeria monocytogenes-based vaccines have been developed to drive tumor specific T-cell responses. Here, we discuss recent preclinical studies using L. monocytogenes vaccines, innate immune pathways that influence T-cell priming, and new vaccine strategies in clinical trials. RECENT
FINDINGS: Recent studies indicate that in addition to inducing antigen specific T-cell responses, L. monocytogenes vaccines remodel the TME. In addition, several innate immune pathways influence adaptive immune responses to L. monocytogenes and modulating these pathways holds promise to enhance anti-tumor T-cell responses.
SUMMARY: The interplay between innate and adaptive immune responses to L. monocytogenes is poorly understood. Understanding these interactions will facilitate the design of better anti-cancer vaccines and improved use of combination therapies.

Entities:  

Keywords:  Listeria monocytogenes; adaptive immunity; cancer vaccines; immunotherapy; innate immunity; tumor-microenvironment

Year:  2019        PMID: 33072493      PMCID: PMC7560980          DOI: 10.1007/s40588-019-00133-4

Source DB:  PubMed          Journal:  Curr Clin Microbiol Rep        ISSN: 2196-5471


  126 in total

1.  STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.

Authors:  Juan Fu; David B Kanne; Meredith Leong; Laura Hix Glickman; Sarah M McWhirter; Edward Lemmens; Ken Mechette; Justin J Leong; Peter Lauer; Weiqun Liu; Kelsey E Sivick; Qi Zeng; Kevin C Soares; Lei Zheng; Daniel A Portnoy; Joshua J Woodward; Drew M Pardoll; Thomas W Dubensky; Young Kim
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).

Authors:  Dung T Le; Vincent J Picozzi; Andrew H Ko; Zev A Wainberg; Hedy Kindler; Andrea Wang-Gillam; Paul Oberstein; Michael A Morse; Herbert J Zeh; Colin Weekes; Tony Reid; Erkut Borazanci; Todd Crocenzi; Noelle K LoConte; Benjamin Musher; Dan Laheru; Aimee Murphy; Chan Whiting; Nitya Nair; Amanda Enstrom; Sandy Ferber; Dirk G Brockstedt; Elizabeth M Jaffee
Journal:  Clin Cancer Res       Date:  2019-05-24       Impact factor: 12.531

4.  A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Authors:  Bridget P Keenan; Yvonne Saenger; Michel I Kafrouni; Ashley Leubner; Peter Lauer; Anirban Maitra; Agnieszka A Rucki; Andrew J Gunderson; Lisa M Coussens; Dirk G Brockstedt; Thomas W Dubensky; Raffit Hassan; Todd D Armstrong; Elizabeth M Jaffee
Journal:  Gastroenterology       Date:  2014-03-06       Impact factor: 22.682

5.  Listeria monocytogenes engineered to activate the Nlrc4 inflammasome are severely attenuated and are poor inducers of protective immunity.

Authors:  John-Demian Sauer; Sabine Pereyre; Kristina A Archer; Thomas P Burke; Bill Hanson; Peter Lauer; Daniel A Portnoy
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

6.  Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3.

Authors:  Thirumala-Devi Kanneganti; Nesrin Ozören; Mathilde Body-Malapel; Amal Amer; Jong-Hwan Park; Luigi Franchi; Joel Whitfield; Winfried Barchet; Marco Colonna; Peter Vandenabeele; John Bertin; Anthony Coyle; Ethan P Grant; Shizuo Akira; Gabriel Núñez
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

Review 7.  Listeriolysin O: the Swiss army knife of Listeria.

Authors:  Mélanie Anne Hamon; David Ribet; Fabrizia Stavru; Pascale Cossart
Journal:  Trends Microbiol       Date:  2012-05-30       Impact factor: 17.079

8.  Listeria-based cancer vaccines that segregate immunogenicity from toxicity.

Authors:  Dirk G Brockstedt; Martin A Giedlin; Meredith L Leong; Keith S Bahjat; Yi Gao; William Luckett; Weiqun Liu; David N Cook; Daniel A Portnoy; Thomas W Dubensky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-13       Impact factor: 11.205

9.  A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer.

Authors:  Partha Basu; Ajay Mehta; Minish Jain; Sudeep Gupta; Rajnish V Nagarkar; Subhashini John; Robert Petit
Journal:  Int J Gynecol Cancer       Date:  2018-05       Impact factor: 3.437

Review 10.  Genetics and biology of pancreatic ductal adenocarcinoma.

Authors:  Haoqiang Ying; Prasenjit Dey; Wantong Yao; Alec C Kimmelman; Giulio F Draetta; Anirban Maitra; Ronald A DePinho
Journal:  Genes Dev       Date:  2016-02-15       Impact factor: 11.361

View more
  3 in total

Review 1.  Microbiome engineering: engineered live biotherapeutic products for treating human disease.

Authors:  Jack W Rutter; Linda Dekker; Kimberley A Owen; Chris P Barnes
Journal:  Front Bioeng Biotechnol       Date:  2022-09-16

Review 2.  Non-human Primate Models to Investigate Mechanisms of Infection-Associated Fetal and Pediatric Injury, Teratogenesis and Stillbirth.

Authors:  Miranda Li; Alyssa Brokaw; Anna M Furuta; Brahm Coler; Veronica Obregon-Perko; Ann Chahroudi; Hsuan-Yuan Wang; Sallie R Permar; Charlotte E Hotchkiss; Thaddeus G Golos; Lakshmi Rajagopal; Kristina M Adams Waldorf
Journal:  Front Genet       Date:  2021-07-05       Impact factor: 4.599

Review 3.  Microbiota and cancer: current understanding and mechanistic implications.

Authors:  A A Khan; A T Sirsat; H Singh; P Cash
Journal:  Clin Transl Oncol       Date:  2021-08-13       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.